PPT-ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients

ASCEND Randomized placebocontrolled trial of aspirin 100 mg daily in 15480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study Collaborative. John J Cannell, MD. Executive Director, Vitamin D Council. The Use of Vitamin D in Clinical Practice. Disclosures. I am paid a salary as the Executive Director of the Vitamin D Council, a 501(c)(3) non-profit.. د. حسين محمد جمعة . اختصاصي الامراض الباطنة . . البورد العربي . كلية طب الموصل . . . . 2011. . . 埼玉医科大学　総合医療センター　内分泌・糖尿病内科. Department of Endocrinology and Diabetes, . Saitama Medical Center, Saitama Medical University. 松田　昌文　. Matsuda, Masafumi. Deepak L. Bhatt, MD, MPH. Professor . of Medicine, Harvard Medical School. Executive Director of Interventional Cardiovascular Programs. Brigham & Women’s Hospital Heart and Vascular Center. Boston, Massachusetts. Aspirin in Primary Prevention, GLP-1 Agonists, Metformin, Psychotropic Drug Monitoring. Nathan Bertsch, PharmD. Mitchell Elting, MD. Most patients should not take aspirin for primary prevention of cardiovascular disease. 140 mg Q2W or 420 mg QM. Placebo SC. Q2W or QM. LDL-C . ≥70 mg/. dL. or. non-HDL-C . ≥100 mg/. dL. Follow-up Q 12 weeks. Screening, Lipid Stabilization, and Placebo Run-in. High or moderate intensity statin therapy . in 2018. 3 Settings for Initiating Aspirin. Serious Vascular Events in Primary Prevention Trials. USPSTF Analysis. USPSTF 2016 Statement of Aspirin Use. Contemporary Clinical Trials Exploring the Role of Aspirin for Cardioprevention. The Role of Aspirin Today. Our Good Old Friend Aspirin. Earlier Primary Prevention Trials: . Aspirin Favored for Serious Vascular Events. Physicians. '. Health Study. Contemporary Aspirin Clinical Trials. Robert J. Mentz, M. Angelyn Bethel, Peter Merrill, Yuliya Lokhnygina, John B. . Buse. , Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter . Michel Cucherat. Lyon. Liens d’intérêt en oncologie. BMS, MSD, Bayer, Novartis, . Gilead. Finalité pratique. Identifier si un essai thérapeutique démontre ou non l’intérêt clinique d’un nouveau traitement. 1. Queiroz LP, Peres MF, Piovesan EJ et al. . A nationwide population-based study of migraine in Brazil. . Cephalalgia. 2009;29(6):642-9.. 2. Queiroz LP, Silva Junior AA. . The prevalence and impact of headache in Brazi. Metabolic Dysfunction-Associated Steatotic Liver Disease . Katherine R. Tuttle,. 1. Thomas Idorn,. 2. Maximilian Jara,. 3. . Mads Sundby Palle,. 2. Anne-Sophie Sejling,. 2. Henning Gr. ønbæk. 4. John McMurray. BHF Cardiovascular Research Centre, University of Glasgow . & Queen Elizabeth University Hospital, Glasgow, UK.. On behalf of the DAPA-HF Committees and Investigators. Results in Nondiabetic Patients. Margy. . Maira. , PhD PT. . UNM Pain Consultation and Treatment Center. no disclosures. Objectives. To feel more confident treating patients with fibromyalgia. Briefly review diagnostic criteria for fibromyalgia.